In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension

Pathophysiology and Mechanisms
Pulmonary Hypertension
ESC Working Groups


Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening cardiovascular disease characterized by obstruction of pulmonary artery branches by unresolved thrombofibrotic material and is classified as group 4 of pulmonary hypertension (PAH). Currently, there is no therapy to ‚prevent‘ development of CTEPH after venous thromboembolism, and treatment consists mostly of surgical extraction of the thrombofibrotic material. Mutation of genes encoding TGFβ signaling molecules have been implicated in the pathophysiology of other forms of pulmonary arterial hypertension. Furthermore, endothelin receptor antagonists are one of the main therapeutic components in the management of patients with PAH and it has been shown that endothelin-1 play a role in pulmonary artery vasoconstriction, pulmonary arterial smooth muscle cell proliferation and pulmonary hypertension.

In the manuscript entitled: "Activated endothelial TGFβ1 signaling promotes venous thrombus non-resolution in mice via endothelin-1: potential role for Chronic Thromboembolic Pulmonary Hypertension" by Bochenek ML et al, using two transgenic mouse lines (platelets-specific deletion of TGFβ1 and endothelial-specific deletion of TGFβRII), pulmonary endarterectomy specimens of patients with CTEPH and human and mouse pulmonary endothelial cells, the authors showed that increased TGFβ1 signaling in endothelial cells via ALK5/TGFβRI receptors delays the resolution of venous thrombi in mice and results in chronic pulmonary thromboembolism. Furthermore, they identified activated TGFβ signaling and plasma levels of endothelin-1 (ET-1) as a potential pathomechanism underlying venous thrombus non-resolution and thromboembolism. Finally, upon inhibition of ET-1 with bosentan (ET-1 receptor antagonist) the authors reversed the conversion of endothelial cells to myofibroblasts (endothelial-to-mesenchymal transition) and improved venous thrombus resolution but also inhibited thrombotic pulmonary obstruction.

Comments by the Author (Dr. M.L. Bochenek):

The authors believe that shown mechanism provide a pathophysiological basis of current clinical practice and may have clinically relevant implications for patients with, or at risk of developing CTEPH.

References


Circ Res. 2020 Jan 17;126(2):162-181

Sharma S, Lang IM. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb Res. 2018;164:136– 144.

Naito A, Sakao S, Lang IM, Voelkel NF, Jujo T, Ishida K, Sugiura T, Matsumiya, G, Yoshino I, Tanabe N, et al. Endothelial cells from pulmonary endarterectomy specimens possess a high angiogenic potential and express high levels of hepatocyte growth factor. BMC Pulm Med. 2018;18:197

Notes to editor


Please use this link to address an email to F.A. (Erik) Klok

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

ESC Working Group on Pulmonary Circulation & Right Ventricular Function

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903, Sophia Antipolis, FR

Tel: +33.4.92.94.76.00